| Stage | DVN | % of rev | OXY | % of rev | Gap · A − B |
|---|---|---|---|---|---|
| Revenue | $7.4B | 100.00% | $8.1B | 100.00% | OXY ×1.09 |
| Gross profit | $4.2B | 55.95% | $6.1B | 76.17% | OXY +20.2pp |
| Operating income | $2.3B | 31.31% | $3.8B | 47.20% | OXY +15.9pp |
| Pre-tax income | $2.4B | 32.14% | $3.9B | 48.54% | OXY +16.4pp |
| Net income | $1.9B | 25.77% | $3.0B | 37.15% | OXY +11.4pp |
| Stage | DVN | OXY | Gap · A − B |
|---|---|---|---|
| Revenue | $7.4B100.00% | $8.1B100.00% | OXY ×1.09 |
| Gross profit | 55.95%$4.2B | 76.17%$6.1B | OXY +20.2pp |
| Operating income | 31.31%$2.3B | 47.20%$3.8B | OXY +15.9pp |
| Pre-tax income | 32.14%$2.4B | 48.54%$3.9B | OXY +16.4pp |
| Net income |
| 25.77%$1.9B |
| 37.15%$3.0B |
| OXY +11.4pp |
None
No disclosed counterparties: DVN.